Cover Image
市場調查報告書

腦轉移 - 開發平台分析

Brain Metastasis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251595
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
Back to Top
腦轉移 - 開發平台分析 Brain Metastasis - Pipeline Review, H2 2015
出版日期: 2015年07月29日 內容資訊: 英文 194 Pages
簡介

腦轉移是在腦部外側組織或器官產生,之後轉移擴大到腦部的腫瘤。症狀有顱內壓的上升、頭痛、嘔吐、意識狀態的變化、局部性神經前兆與發作(癲癇發作)等。 治療方法有化療、手術、放射線治療等。

本報告提供腫瘤的腦轉移的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

腦轉移 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • GlaxoSmithKline plc
  • Eisai
  • Pfizer Inc.
  • Exelixis, Inc.
  • Nanobiotix
  • Spectrum Pharmaceuticals, Inc.
  • Philogen S.p.A.
  • Nerviano Medical Sciences
  • AngioChem Inc.
  • Diffusion Pharmaceuticals LLC
  • to-BBB technologies BV
  • biOasis Technologies Inc.
  • Phosplatin Therapeutics
  • Sagetis Biotech, S.L.
  • Puma Biotechnology, Inc.
  • AbbVie Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • trastuzumab
  • ipilimumab
  • neratinib
  • dacomitinib
  • cabozantinib s-malate
  • lucanthone hydrochloride
  • ANG-1005
  • lapatinib ditosylate
  • veliparib
  • 2B3-101
  • (dabrafenib mesylate + trametinib dimethyl sulfoxide)
  • dabrafenib mesylate
  • cabazitaxel
  • radretumab
  • RAD-1901
  • transcrocetinate sodium
  • PB-357
  • PT-112
  • Recombinant Adenoviral Human p53 Gene Therapy
  • BT-2111
  • ANG-4043
  • NBTX-IV
  • NMSE-973
  • SAG-002
  • SAG-003
  • Drug for Brain metastases

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6938IDB

Summary

Global Markets Direct's, 'Brain metastasis - Pipeline Review, H2 2015', provides an overview of the Brain metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Brain metastasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Brain metastasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Brain metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Brain metastasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Brain metastasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Brain metastasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Brain Metastasis Overview
  • Therapeutics Development
    • Pipeline Products for Brain Metastasis - Overview
    • Pipeline Products for Brain Metastasis - Comparative Analysis
  • Brain Metastasis - Therapeutics under Development by Companies
  • Brain Metastasis - Therapeutics under Investigation by Universities/Institutes
  • Brain Metastasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Brain Metastasis - Products under Development by Companies
  • Brain Metastasis - Products under Investigation by Universities/Institutes
  • Brain Metastasis - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • AngioChem Inc.
    • BBB Therapeutics B.V.
    • biOasis Technologies Inc.
    • Bristol-Myers Squibb Company
    • Diffusion Pharmaceuticals LLC
    • e-Therapeutics Plc
    • Exelixis, Inc.
    • GlaxoSmithKline Plc
    • Hutchison MediPharma Limited
    • Komipharm International Co., Ltd.
    • Nektar Therapeutics
    • Nerviano Medical Sciences S.r.l.
    • Novartis AG
    • Oncothyreon Inc.
    • Pfizer Inc.
    • Philogen S.p.A.
    • Phosplatin Therapeutics LLC
    • Puma Biotechnology, Inc.
    • Radius Health, Inc.
    • Sanofi
    • Spectrum Pharmaceuticals, Inc.
    • Tocagen Inc.
  • Brain Metastasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 2B3-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANG-1005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANG-4043 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BT-2111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ceritinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dacomitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etirinotecan pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETS-2101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-813 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipilimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irbinitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KML-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lucanthone hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDNA-55 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • neratinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NMSE-973 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-357 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06463922 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plinabulin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PT-112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RAD-1901 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radretumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RRX-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TPI-287 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • transcrocetinate sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Metastatic Brain Tumor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • veliparib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vocimagene amiretrorepvec + flucytosine ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • X-82 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Brain Metastasis - Recent Pipeline Updates
  • Brain Metastasis - Dormant Projects
  • Brain Metastasis - Discontinued Products
  • Brain Metastasis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 28, 2014: Radius Health Reports Proof of Mechanism for RAD1901 and Presentation at 4th Annual Brain Metastases Research and Emerging Therapy Conference in September
      • Nov 12, 2013: Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone
      • Oct 08, 2013: Angiochem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
      • Jul 29, 2013: Nerviano Medical Sciences researchers report data on a novel molecule inhibitor of HSP90
      • Apr 09, 2013: biOasis Provides Update On BT2111-Herceptin Program
      • Dec 03, 2012: Geron Discontinues Development Of Brain Cancer Drug Candidate GRN1005
      • Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer
      • Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC
      • Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Brain Metastases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Brain Metastasis, H2 2015
  • Number of Products under Development for Brain Metastasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Brain Metastasis - Pipeline by AbbVie Inc., H2 2015
  • Brain Metastasis - Pipeline by AngioChem Inc., H2 2015
  • Brain Metastasis - Pipeline by BBB Therapeutics B.V., H2 2015
  • Brain Metastasis - Pipeline by biOasis Technologies Inc., H2 2015
  • Brain Metastasis - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Brain Metastasis - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015
  • Brain Metastasis - Pipeline by e-Therapeutics Plc, H2 2015
  • Brain Metastasis - Pipeline by Exelixis, Inc., H2 2015
  • Brain Metastasis - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Brain Metastasis - Pipeline by Hutchison MediPharma Limited, H2 2015
  • Brain Metastasis - Pipeline by Komipharm International Co., Ltd., H2 2015
  • Brain Metastasis - Pipeline by Nektar Therapeutics, H2 2015
  • Brain Metastasis - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
  • Brain Metastasis - Pipeline by Novartis AG, H2 2015
  • Brain Metastasis - Pipeline by Oncothyreon Inc., H2 2015
  • Brain Metastasis - Pipeline by Pfizer Inc., H2 2015
  • Brain Metastasis - Pipeline by Philogen S.p.A., H2 2015
  • Brain Metastasis - Pipeline by Phosplatin Therapeutics LLC, H2 2015
  • Brain Metastasis - Pipeline by Puma Biotechnology, Inc., H2 2015
  • Brain Metastasis - Pipeline by Radius Health, Inc., H2 2015
  • Brain Metastasis - Pipeline by Sanofi, H2 2015
  • Brain Metastasis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
  • Brain Metastasis - Pipeline by Tocagen Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Brain Metastasis Therapeutics - Recent Pipeline Updates, H2 2015
  • Brain Metastasis - Dormant Projects, H2 2015
  • Brain Metastasis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Brain Metastasis, H2 2015
  • Number of Products under Development for Brain Metastasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top